AptaBio Therapeutics Inc
KOSDAQ:293780
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cenkos Securities PLC
LSE:CNKS
|
UK |
|
TPV Technology Co Ltd
SZSE:000727
|
CN |
|
Vivara Participacoes SA
BOVESPA:VIVA3
|
BR |
AptaBio Therapeutics Inc
EPS (Diluted)
AptaBio Therapeutics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
AptaBio Therapeutics Inc
KOSDAQ:293780
|
EPS (Diluted)
-₩752
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
EPS (Diluted)
₩4.7k
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
17%
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
EPS (Diluted)
-₩1.9k
|
CAGR 3-Years
-14%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
EPS (Diluted)
₩2.6k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
55%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
EPS (Diluted)
-₩734
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
EPS (Diluted)
-₩705
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
AptaBio Therapeutics Inc
Glance View
Aptabio Therapeutics, Inc. operates as a pharmaceutical biotechnology company that develops intractable innovative drugs based on original platform technology. The company is headquartered in Yongin, Gyeonggi-Do and currently employs 28 full-time employees. The company went IPO on 2019-06-12. The firm is developing anti-cancer drugs, drugs for inflammatory and fibrotic diseases and diabetic complications drugs, among others.
See Also
What is AptaBio Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-752.4
KRW
Based on the financial report for Sep 30, 2025, AptaBio Therapeutics Inc's EPS (Diluted) amounts to -752.4 KRW.
What is AptaBio Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-17%
Over the last year, the EPS (Diluted) growth was 12%. The average annual EPS (Diluted) growth rates for AptaBio Therapeutics Inc have been -9% over the past three years , -17% over the past five years .
